Advertisement

Effects of perindopril on cardiovascular remodeling

  • Gary E McVeigh
    Correspondence
    Address for reprints: Gary E. McVeigh, MD, PhD, The Queen’s University of Belfast, Department of Therapeutics and Pharmacology, Whitla Medical Building, Belfast, Northern Ireland
    Affiliations
    Department of Therapeutics and Pharmacology, The Queen’s University of Belfast, Belfast, Northern Ireland UK
    Search for articles by this author

      Abstract

      The primary aim in the medical treatment of hypertension is to lower blood pressure (BP). A wide variety of agents have proved effective for meeting this goal. However, an ideal agent for management of hypertensive patients must also meet a number of additional criteria. It should have a significant positive impact on conditions that are likely to be associated with elevated BP and that are known risk factors for cardiovascular morbidity and mortality. This article reviews effects of the long-acting angiotensin-converting enzyme inhibitor perindopril erbumine on hypertension-associated blood vessel and myocardial remodeling known to be associated with increased cardiovascular risk. Long-term treatment with perindopril improves arterial compliance and increases the media–lumen ratio of peripheral resistance vessels. These effects appear to be at least partially independent of BP lowering. Reversal of hypertension-associated vascular remodeling with perindopril should decrease afterload and reduce or reverse left ventricular hypertrophy. Evaluation of patients who have received long-term perindopril therapy has shown this to be the case. This effect of perindopril on an important predictor of cardiovascular morbidity and mortality may also be partially independent of BP. The combination of treatment with such agents as perindopril and methods that permit early detection of vascular changes contributing to cardiovascular disease has the potential to markedly improve the prognosis for hypertensive patients and others at risk for development of cardiovascular disease.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • National High Blood Pressure Education Program Working Group
        report on hypertension in the elderly.
        Hypertension. 1994; 23: 275-285
        • Dahlöf B
        • Hansson L
        • Hindholm L.H
        • Scherstén B
        • Ekbom T
        • Wester P.-O
        Swedish Trial in Old Patients with Hypertension (STOP-hypertension) analyses performed up to 1992.
        Clin Exp Hypertens. 1993; 15: 925-939
        • SHEP Cooperative Research Group
        Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension.
        JAMA. 1991; 265: 3255-3264
        • Waeber B
        • Brunner H.R
        Cardiovascular hypertrophy.
        J Cardiovasc Pharmacol. 1996; 27: S36-S40
        • Rosendorff C
        Vascular hypertrophy in hypertension.
        Mt Sinai J Med. 1998; 65: 108-117
        • Plante G.E
        The blood vessel as a target organ in hypertension.
        Can J Cardiol. 1994; 10: 25D-29D
        • Weir M.R
        • Dzau V.J
        The renin-angiotensin-aldosterone system.
        Am J Hypertens. 1999; 12: 205S-213S
        • Goodfriend T.L
        • Elliott M.E
        • Catt K.J
        Angiotensin receptors and their antagonists.
        N Engl J Med. 1996; 334: 1649-1654
        • Hahn A.W
        • Resink T.J
        • Mackie E
        • Scott-Burden T
        • Buhler F.R
        Effects of peptide vasoconstrictors on vessel structure.
        Am J Med. 1993; 94: 13S-19S
        • Williams B
        • Baker A.Q
        • Gallacher B
        • Lodwick D
        Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells.
        Hypertension. 1995; 25: 913-917
        • Giles T.D
        Angiotensin-converting enzyme inhibition, cell growth, and left ventricular hypertrophy in hypertension.
        Clin Cardiol. 1991; 14: IV63-IV67
        • Schmidt-Ott K.M
        • Kagiyama S
        • Phillips M.I
        The multiple actions of angiotensin II in atherosclerosis.
        Regul Pept. 2000; 93: 65-77
        • Kahan T
        The importance of left ventricular hypertrophy in human hypertension.
        J Hypertens Suppl. 1998; 17: S23-S29
        • Todd P.A
        • Fitton A
        Perindopril.
        Drugs. 1991; 42: 90-114
        • Michel J.-B
        • Levy B.I
        Vascular effects of ACE inhibition by perindopril.
        Drugs. 1990; 39: 39-42
        • Zhuo J.L
        • Froomes P
        • Casley D
        • Liu J.J
        • Murone C
        • Chai S.Y
        • Buxton B
        • Mendelsohn F.A.O
        Perindopril chronically inhibits angiotensin-converting enzyme in both the endothelium and adventitia of the internal mammary artery in patients with ischemic heart disease.
        Circulation. 1997; 96: 174-182
        • Sihm I
        • Schroeder A.P
        • Aalkjaer C
        • Holm M
        • Mørn B
        • Mulvany M
        • Thygesen K
        • Lederballe O
        Normalization of structural cardiovascular changes during antihypertensive treatment with a regimen based on the ACE-inhibitor perindopril.
        Blood Press. 1995; 4: 241-248
        • Schwartzkopff B
        • Brehm M
        • Mundhenke M
        • Strauer B.E
        Repair of coronary arterioles after treatment with perindopril in hypertensive heart disease.
        Hypertension. 2000; 36: 220-225
        • Bijlstra P.J
        • Smits P
        • Lutterman J.A
        • Thien T
        Effect of long-term angiotensin-converting enzyme inhibition on endothelial function in patients with the insulin-resistance syndrome.
        J Cardiovasc Pharmacol. 1995; 25: 658-664
        • Giugliano D
        • Giunta R
        • Marfella R
        • Coppola L
        • Acampora R
        • D’onofrio F
        Effects of perindopril and carvedilol on endothelium-dependent vascular functions in patients with diabetes and hypertension.
        Diabetes Care. 1998; 21: 631-636
        • Mitchell G.F
        Pulse pressure, arterial compliance and cardiovascular morbidity and mortality.
        Curr Opin Nephrol Hypertens. 1999; 8: 335-342
        • Asmar R.G
        • Pannier B
        • Santoni J.P
        • Laurent S
        • London G.M
        • Levy B.I
        • Safar M.E
        Reversion of cardiac hypertrophy and reduced arterial compliance after converting enzyme inhibition in essential hypertension.
        Circulation. 1988; 78: 941-950
        • O’Rourke M.F
        Wave travel and reflection in the arterial system.
        J Hypertens. 1999; 17: S45-S47
        • Kool M.J
        • Lustermans F.A
        • Breed J.G
        • Boudier H.A
        • Hoeks A.P
        • Renemen R.S
        • van Bortel L.M
        • Struyker
        The influence of perindopril and the diuretic combination amiloride + hydrochlorothiazide on the vessel wall properties of large arteries in hypertensive patients.
        J Hypertens. 1995; 13: 839-848
        • Scalbert E
        • Levy B
        • Desche P
        • Devissague T.M
        • Safar M.E
        Vascular effects of perindopril.
        J Cardiovasc Pharmacol. 1991; 18: S25-S32
        • Benetos A
        • Cambien F
        • Gautier S
        • Richard S
        • Safar M
        • Laurent S
        • Lacolley P
        • Poirier O
        • Topouchian J
        • Asmar R
        Influence of the angiotensin II type 1 receptor gene polymorphism on the effects of perindopril and nitrendipine on arterial stiffness in hypertensive individuals.
        Hypertension. 1996; 28: 1081-1084
        • Brinton T.J
        • Kailasam M.T
        • Wu R.A
        • Cervenka J.H
        • Chio S.-S
        • Parmer R.J
        • DeMaria A.N
        • O’Connor D.T
        Arterial compliance by cuff sphygmomanometer.
        Hypertension. 1996; 28: 599-603
        • Messerli F.H
        • Frolich E.D
        • Ventura H.O
        Arterial compliance in essential hypertension.
        J Cardiovasc Pharmacol. 1985; 7: S33-S35
      1. Asmar R, Topouchian J, Pannier B, Rudnichi A, Safar M. Reversion of arterial abnormalities by long-term antihypertensive therapy in large population: the COMPLIOR study. Presented at the 9th European Society of Hypertension Meeting; June 11–15, 1999; Milan, Italy.

        • Stumpe K.O
        • Ludwig M
        • Heagerty A.M
        • Kolloch R.E
        • Mancia G
        • Safar M
        • Zanchetti A
        • PROTECT Study Group
        Vascular wall thickness in hypertension.
        Am J Cardiol. 1995; 76: 50E-54E
        • Giles T.D
        Angiotensin-converting enzyme inhibition, cell growth, and left ventricular hypertrophy in hypertension.
        Clin Cardiol. 1991; 14: IV63-IV67
        • Jennings G.L
        • Wong J
        Reversibility of left ventricular hypertrophy and malfunction by antihypertensive treatment.
        in: Hansson L Birkenhager W.H Assessment of Hypertensive Organ Damage. Handbook of Hypertension. Vol. 18. Elsevier Science BV, Oxford, UK1997: 205-211
        • Revel F
        • Gallois H
        • LeCoz Y
        • Richard R
        • Ollivier J.P
        Évolution de la masse ventriculaire gauche dans une population de 893 hypertendus.
        Ann Cardiol Angeiol. 1994; 43: 594-599
        • Yalcin F
        • Aksoy F.G
        • Muderrisoglu H
        • Sabah I
        • Garcia M.J
        • Thomas J.D
        Treatment of hypertension with perindopril reduces plasma atrial natriuretic peptide levels, left ventricular mass, and improves echocardiographic parameters of diastolic function.
        Clin Cardiol. 2000; 23: 437-441
        • Schulte K.-L
        • Meyer-Sabellek W
        • Liederwald K
        • van Gemmeren D
        • Lenz T
        • Gotzen R
        Relation of regression of left ventricular hypertrophy to changes in ambulatory blood pressure after long-term therapy with perindopril versus nifedipine.
        Am J Cardiol. 1992; 70: 468-473
        • Grandi A.M
        • Bignotti M
        • Gaudio G
        • Zanzi P
        • Guasti L
        • Venco A
        Ambulatory blood pressure and left ventricular changes during antihypertensive treatment.
        J Cardiovasc Pharmacol. 1995; 26: 737-741
        • Frohlich E.D
        Risk mechanisms in hypertensive heart disease.
        Hypertension. 1999; 34: 782-789
        • Neutel J.M
        • Smith D.H.G
        Hypertension.
        Am J Hypertens. 1998; 11: 150S-157S